Malin Corporation plc (MLC.IR)

7.48 €

+0.08 (+1.08%)
Rating:
Recommendation:
-
Symbol MLC.IR
Price 7.48 €
Beta 1.160
Volume Avg. 0.03M
Market Cap 309.088M
Shares () -
52 Week Range 3.59-7.64
1y Target Est -
DCF Unlevered MLC.IR DCF ->
DCF Levered MLC.IR LDCF ->
ROE -6.33% Neutral
ROA -7.90% Neutral
Operating Margin -
Debt / Equity 2.86% Neutral
P/E 57.54 Strong Buy
P/B 1.78 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Darragh Fergal Lyons
Healthcare
Drug Manufacturers—Specialty & Generic
Irish

Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It offers life-saving cell and gene therapies for patients with high unmet medical need; medicines to address unmet needs in cancer, infection, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis or fungal nail infection. The company also provides drugs for protein misfolding diseases; and platform to distinguish disease-driving bacteria from the intestinal microbiota, as well as UV-light disinfection technology solutions. In addition, it provides company secretarial services. Malin Corporation plc was incorporated in 2014 and is headquartered in Dublin, Ireland.